These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22191248)

  • 1. [Results of chemotherapy for gynecologic cancer patients in ambulatory care].
    Protasova AE; Orlova RV
    Vopr Onkol; 2011; 57(4):525-9. PubMed ID: 22191248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
    Nagao S; Okimoto N; Hongo A; Mizutani Y; Kodama J; Yoshinouchi M; Hiramatsu Y; Kudo T
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
    Maurer K; Michener C; Mahdi H; Rose PG
    J Gynecol Oncol; 2017 Jul; 28(4):e38. PubMed ID: 28541630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs in gynecologic oncology.
    Eisenhauer EA; Vermorken JB
    Curr Opin Oncol; 1996 Sep; 8(5):408-14. PubMed ID: 8914808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future directions in the chemotherapy of ovarian cancer.
    Ozols RF
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
    Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
    Matulonis U; Campos S; Duska L; Fuller A; Berkowitz R; Gore S; Roche M; Colella T; Lee H; Seiden MV; ;
    Gynecol Oncol; 2003 Nov; 91(2):293-8. PubMed ID: 14599858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Outpatient chemotherapy in gynecologic oncology].
    Jobo T
    Gan To Kagaku Ryoho; 2006 Dec; 33 Suppl 2():369-71. PubMed ID: 17469390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of chemotherapy in gynecologic cancer.
    Tropé C; Kristensen G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-1-S15-22. PubMed ID: 9346216
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy for gynecologic malignancies at Siriraj Hospital, Bangkok.
    Senapad S
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):656-9. PubMed ID: 3939044
    [No Abstract]   [Full Text] [Related]  

  • 14. Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study.
    Ota S; Sugiyama T; Komai K; Hirai N; Kumagai S; Ushijima K; Nishida T; Kamura T
    Jpn J Clin Oncol; 2001 Aug; 31(8):395-8. PubMed ID: 11574633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium.
    Pecorelli S; Angioli R; Favalli G; Odicino F
    Cancer Chemother Biol Response Modif; 2003; 21():565-84. PubMed ID: 15338764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic.
    Ishikawa M; Kawai M; Maeda T; Kagawa Y
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):399-411. PubMed ID: 29299638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the chemotherapy of gynecologic cancer.
    Neijt JP
    Curr Opin Oncol; 1994 Sep; 6(5):531-8. PubMed ID: 7827159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
    Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.